The multifaceted relationship between IL-10 and adaptive immunity: putting together the pieces of a puzzle

被引：205

作者：

Mocellin, S

Marincola, F

Rossi, CR

Nitti, D

Lise, M

机构：

[1] Univ Padua, Clin Chirurg 2, Dept Oncol & Surg Sci, I-35128 Padua, Italy

[2] NIH, Dept Transfus Med, Immunogenet Sect, Bethesda, MD USA

来源：

CYTOKINE & GROWTH FACTOR REVIEWS | 2004年 / 15卷 / 01期

关键词：

IL-10; adaptive immunity; cytotoxic T lymphocyte;

D O I：

10.1016/j.cytogfr.2003.11.001

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Interleukin-10 (IL-10) is a pleiotropic cytokine that modulates the function of several adaptive immunity-related cells. Although generally considered an immunosuppressive molecule, IL-10 possesses immunostimulatory properties in several in vitro and in vivo models. These very different outcomes are believed to depend upon experimental conditions, the dominant immune effector mediating a given immune response, the timing of IL-10 production/administration, and IL-10 dose and/or location of expression. In the present work, we review the current knowledge regarding IL-10 activity on adaptive immunity related cells, emphasize new insights on IL-10 molecular/cellular targets, and summarize the available data on the relationship between IL-10 and some pathological conditions (e.g. infectious diseases, autoimmunity, allergy, cancer and transplantation) involving adaptive immunity. (C) 2003 Elsevier Ltd. All rights reserved.

引用

收藏

页码：61 / 76

页数：16

相关论文

共 220 条

[1] IL-10 induces a Th2 cell tolerance in allergic asthma [J].

Adachi, M ;

Oda, N ;

Kokubu, F ;

Minoguchi, K .

INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 1999, 118 (2-4) :391-394

[2] IL-10 expression by CT26 colon carcinoma cells inhibits their malignant phenotype and induces a T cell-mediated tumor rejection in the context of a systemic Th2 response [J].

Adris, SK ;

Klein, S ;

Jasnis, MA ;

Chuluyan, E ;

Ledda, MF ;

Bravo, AI ;

Carbone, C ;

Chernajovsky, Y ;

Podhajcer, OL .

GENE THERAPY, 1999, 6 (10) :1705-1712

[3] Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma [J].

Agarwala, SS ;

Glaspy, J ;

O'Day, SJ ;

Mitchell, M ;

Gutheil, J ;

Whitman, E ;

Gonzalez, R ;

Hersh, E ;

Feun, L ;

Belt, R ;

Meyskens, F ;

Hellstrand, K ;

Wood, D ;

Kirkwood, JM ;

Gehlsen, KR ;

Naredi, P .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) :125-133

[4] Generation of plasma cells from peripheral blood memory B cells: Synergistic effect of interleukin-10 and CD27/CD70 interaction [J].

Agematsu, K ;

Nagumo, H ;

Oguchi, Y ;

Nakazawa, T ;

Fukushima, K ;

Yasui, K ;

Ito, S ;

Kobata, T ;

Morimoto, C ;

Komiyama, A .

BLOOD, 1998, 91 (01) :173-180

[5] Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen [J].

Akbari, O ;

DeKruyff, RH ;

Umetsu, DT .

NATURE IMMUNOLOGY, 2001, 2 (08) :725-731

[6] Role of interleukin 10 in specific immunotherapy [J].

Akdis, CA ;

Blesken, T ;

Akdis, M ;

Wüthrich, B ;

Blaser, K .

JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (01) :98-106

[7] Mechanisms of interleukin-10-mediated immune suppression [J].

Akdis, CA ;

Blaser, K .

IMMUNOLOGY, 2001, 103 (02) :131-136

[8] Suppressors of cytokine signalling (SOCS) in the immune system [J].

Alexander, WS .

NATURE REVIEWS IMMUNOLOGY, 2002, 2 (06) :410-416

[9] Interleukin-10 (IL-10) secretion in systemic lupus erythematosus and rheumatoid arthritis: IL-10-dependent CD4+CD45RO+ T cell B cell antibody synthesis [J].

AlJanadi, M ;

AlDalaan, A ;

AlBalla, S ;

AlHumaidi, M ;

Raziuddin, S .

JOURNAL OF CLINICAL IMMUNOLOGY, 1996, 16 (04) :198-207

[10]

Allavena P, 1998, EUR J IMMUNOL, V28, P359, DOI 10.1002/(SICI)1521-4141(199801)28:01<359::AID-IMMU359>3.0.CO

← 1 2 3 4 5 6 7 8 9 10 →